Gelonghui, March 5 | Minimally Invasive Robot-B (02252.HK) announced that in the face of a complex and changing external environment, in 2023, the Group will adhere to a business-focused strategy with the primary goal of promoting sustainable business growth, and continuously and thoroughly improve operational efficiency. With extensive multi-track layout, excellent product performance and industry-leading commercialization strength, the Group's many listed products have made significant progress in domestic commercialization breakthroughs and global expansion.
The board of directors expects the company's revenue for the year ended December 31, 2023 to increase by more than 350% year-on-year compared to the year ended December 31, 2022. This increase is mainly due to the continuous increase in sales revenue due to the comprehensive commercialization process of the group's products Tumai quadrilateral endoscopic surgery robot (“Tumai”), Honghu joint replacement surgery robot, and Dragonfly Eye 3D electronic laparoscopy.
The board of directors expects the company to record a net loss of no more than RMB 1,050 million for the year ended 31 December 2023 (year ended 31 December 2022: RMB 1,146 million). The expected net loss reduction is mainly due to (i) increased gross profit due to increased operating income; and (ii) lower R&D expenses due to focusing on core R&D projects and improving R&D efficiency. However, sales expenses increased due to full commercial activities to promote various products already listed by the Group during the period. The business focus was on generating additional one-time adjustment expenses (such as expenses related to rental site adjustments), inventory price reduction preparations calculated with signs of impairment of some inventory, and loss of fair value changes in overseas investments held by the Group partially offset the impact of these factors.
Up to now, the Group has shown good commercialization momentum and progress in globalization. In particular, since the Tumaido department registration was approved in October 2023, the domestic bid process has been clearly accelerated, and overseas orders have been successfully obtained, continuing to consolidate the company's leading position in the domestic brand market. At the same time, various cost reduction and efficiency measures effectively implemented during the period are expected to lay a good foundation for improving the Group's subsequent profitability.
In the future, the Group will focus on promoting the continuous growth of sales revenue from its diverse product portfolio at home and abroad, maintaining the company's ability to innovate and rapidly transform R&D results, further explore, optimize and improve operational efficiency, and create greater value for the company's shareholders and the industry.